Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15,304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Lazertinib versus Gefitinib as First-Line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.
Lee KH, Cho BC, Ahn MJ, Lee YG, Lee Y, Lee JS, Kim JH, Min YJ, Lee GW, Lee SS, Lee KH, Ko YH, Shim BY, Kim SW, Shin SW, Choi JH, Kim DW, Cho EK, Park KU, Kim JS, Chun SH, Wang J, Choi S, Kang JH. Lee KH, et al. Among authors: kim dw, kim sw, kim js, kim jh. Cancer Res Treat. 2024 Jan;56(1):48-60. doi: 10.4143/crt.2023.453. Epub 2023 Jun 27. Cancer Res Treat. 2024. PMID: 37402411 Free PMC article. Clinical Trial.
Open-label, randomized comparison of the efficacy of intravenous dolasetron mesylate and ondansetron in the prevention of acute and delayed cisplatin-induced emesis in cancer patients.
Kim JS, Baek JY, Park SR, Choi IS, Kim SI, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Kim JS, et al. Among authors: kim dw, kim ty, kim si, kim nk. Cancer Res Treat. 2004 Dec;36(6):372-6. doi: 10.4143/crt.2004.36.6.372. Epub 2004 Dec 31. Cancer Res Treat. 2004. PMID: 20368831 Free PMC article.
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.
Park S, Keam B, Kim SH, Kim KH, Kim YJ, Kim JS, Kim TM, Lee SH, Kim DW, Lee JS, Heo DS. Park S, et al. Among authors: kim yj, kim dw, kim sh, kim js, kim tm, kim kh. Cancer Res Treat. 2015 Oct;47(4):630-7. doi: 10.4143/crt.2014.244. Epub 2015 Feb 16. Cancer Res Treat. 2015. PMID: 25687850 Free PMC article.
Current Status and Challenges of Cancer Clinical Trials in Korea.
Shim BY, Park SH, Lee S, Kim JS, Lee KE, Kang YK, Ahn MJ. Shim BY, et al. Among authors: kim js. Cancer Res Treat. 2016 Jan;48(1):20-7. doi: 10.4143/crt.2014.317. Epub 2015 Mar 2. Cancer Res Treat. 2016. PMID: 25761486 Free PMC article.
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.
Mok TS, Wu Y-L, Ahn M-J, Garassino MC, Kim HR, Ramalingam SS, Shepherd FA, He Y, Akamatsu H, Theelen WS, Lee CK, Sebastian M, Templeton A, Mann H, Marotti M, Ghiorghiu S, Papadimitrakopoulou VA; AURA3 Investigators. Mok TS, et al. N Engl J Med. 2017 Feb 16;376(7):629-640. doi: 10.1056/NEJMoa1612674. Epub 2016 Dec 6. N Engl J Med. 2017. PMID: 27959700 Free PMC article. Clinical Trial.
Efficacy and safety of controlled-release oxycodone/naloxone versus controlled-release oxycodone in Korean patients with cancer-related pain: a randomized controlled trial.
Lee KH, Kim TW, Kang JH, Kim JS, Ahn JS, Kim SY, Yun HJ, Eum YJ, Koh SA, Kim MK, Hong YS, Kim JE, Lee GW. Lee KH, et al. Among authors: kim tw, kim sy, kim js, kim je, kim mk. Chin J Cancer. 2017 Sep 11;36(1):74. doi: 10.1186/s40880-017-0241-4. Chin J Cancer. 2017. PMID: 28893309 Free PMC article. Clinical Trial.
Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.
Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK. Kim HS, et al. Among authors: kim kc, kim js, kim mj, kim jh. Gastric Cancer. 2018 Sep;21(5):802-810. doi: 10.1007/s10120-018-0794-1. Epub 2018 Jan 25. Gastric Cancer. 2018. PMID: 29372461 Clinical Trial.
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer.
Kim DW, Kim HG, Kim JH, Park K, Kim HK, Jang JS, Kim BS, Kang JH, Lee KH, Kim SW, Ryoo HM, Kim JS, Lee KH, Kwon JH, Choi JH, Shin SW, Hahn S, Heo DS. Kim DW, et al. Among authors: kim hg, kim bs, kim hk, kim sw, kim js, kim jh. Cancer Res Treat. 2019 Jan;51(1):119-127. doi: 10.4143/crt.2018.019. Epub 2018 Mar 12. Cancer Res Treat. 2019. PMID: 29529858 Free PMC article. Clinical Trial.
15,304 results
You have reached the last available page of results. Please see the User Guide for more information.